This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Ocular Therapeutix (Nasdaq:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, will visit the NASDAQ MarketSite in Times Square in celebration of its initial public offering (IPO) which occurred on The NASDAQ Stock Market on July 25, 2014.
In honor of the occasion,
Amar Sawhney, Ph.D.,
President, Chief Executive Officer and Chairman of the Board of Directors, will ring the Closing Bell.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Friday, August 1, 2014 – 3:45 p.m. to 4:00 p.m. ET
Ocular Therapeutix Investor Contacts: Brad Smith Chief Financial Officer
Kimberly Minarovich Burns McClellan on behalf of Ocular Therapeutix (212) 213-0006
firstname.lastname@example.orgOcular Therapeutix Media Contact: Scott Corning Vice President of Sales and Marketing
email@example.comNASDAQ MarketSite: Christine Barna (646) 441-5310
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For photos from ceremonies and events visit our Instagram Page:
For news tweets, please visit our Twitter page at:
For exciting viral content and ceremony photos visit Tumblr Page:
A webcast of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Ocular Therapeutix (Nasdaq:OCUL):
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain and Phase 2 clinical development for glaucoma, ocular hypertension and allergic conjunctivitis. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, was approved by the U.S. Food and Drug Administration in January 2014 to seal corneal incisions following cataract surgery.